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Background: The combination of chemotherapeutic drugs with different pharmacological action has emerged as a
promising therapeutic strategy in the treatment of cancers. Present study examines the antitumor potential of
paclitaxel (PTX) and etoposide (ETP)-loaded PLGA nanoparticles for the treatment of osteosarcoma.
Results: The resulting drug-loaded PLGA NP exhibited a nanosize dimension with uniform spherical morphology.
The NP exhibited a sustained release profile for both PTX and ETP throughout the study period without any sign of
initial burst release. The combinational drug-loaded PLGA NP enhanced the cytotoxic effect in MG63 and Saos-2
osteosarcoma cell lines, in comparison to either native drug alone or in cocktail combinations. Additionally, NPs
showed an appreciable uptake in MG63 cells in a time-based manner. Co-delivery of anticancer drugs resulted in
enhanced cell cycle arrest and cell apoptosis. The results clearly showed that combinational drugs remarkably improved
the therapeutic index of chemotherapeutic drugs. The greater inhibitory effect of nanoparticle combination would be
of great advantage during systemic cancer therapy.
Conclusion: Taken together, our study demonstrated that PTX-ETP/PLGA NP based combination therapy holds
significant potential towards the treatment of osteosarcoma.
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Osteosarcoma (OS) is one of the most prevalent malig-
nant bone cancers affecting adolescents aged between 10
and 24 years [1]. Children and adolescent constitutes
60% of overall bone tumor cases in past 2 decades [2].
Although significant progress have been made in the
treatment of OS (5 year survival rate to 65%), metastatic
cancer which constitutes to only 20% survival rate is a
big cause of concern [3]. The standard treatment proto-
col for this disease mainly includes surgery and conven-
tional chemotherapy. Lungs are most common site of
metastasis followed by other bones [4]. Single drug regi-
men based chemotherapy is the mainstay treatment for
OS. Despite great strides in OS treatment, no substantial
improvement in OS therapy has taken place and remains
elusive [5,6].* Correspondence: yuxiuchun7893@gmail.com
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unless otherwise stated.Cancer therapy based on single drug remains unsatis-
fying due to the complex microenvironment of cancer
cells along with the drug resistance mechanisms [7]. In
this regard, combination therapy has been considered as
a promising strategy to improve the therapeutic effi-
ciency and to minimize side effects [8]. The combination
of two or more chemotherapeutic drugs may act syner-
gistically towards the cancer cell suppression. The ad-
ministration of anticancer drugs with two different
molecular pathways can delay the cancer cell adaptation
process and thereby reduce the cancer cell mutations.
Chemotherapeutic drugs with same molecular pathway
could function synergistically towards the better thera-
peutic efficacy and higher target selectivity [9,10]. In the
present study, paclitaxel (PTX) and etoposide (ETP)
were selected as a unique drug combination for the ef-
fective treatment of OS. PTX has been one of the widely
used anticancer cytotoxic agents approved for the treat-
ment of many malignancies. The cytotoxic action of
PTX results from the interference in microtubuleThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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depolymerization, M-phase cell cycle arrest, and cell
death [11,12]. ETP on the other hand kills the cancer
cells by stabilizing a covalent enzyme-DNA complex
which is an important part of catalytic cycle of topo-
isomerase II. A permanent DNA strand breaks due to
the accumulation of cleaved enzyme complexes, leading
to mutagenesis, chromosomal translocation, and cell
death [13,14]. As the individual efficacy of each of these
two agents is very significant, we planned to evaluate the
combination effect of PTX and ETP in this study.
Despite the significance of combination treatment, ad-
ministration of cocktail combinational regimen did not
result in better therapeutic efficacy [15]. The diverse
pharmacokinetics, biodistribution, and membrane
transport mechanism of two drugs would result in poor
accumulation in cancer cells and attain suboptimal
concentration at tumor site making dosing extremely
difficult. Besides, it resulted in severe drug-related side
effects in the clinical subjects [16]. Therefore, multiple
chemotherapeutic drugs have to be entrapped in single
nanocarriers such that it can release the active molecule in
a predetermined manner. The ideal nanocarrier should
possess high loading capacity for both the drug and should
remain stable in blood circulation for prolonged period of
time so that it can avail enhanced permeability and reten-
tion effect (EPR) [17]. A variety of nanoparticle-based
delivery systems have been developed for the delivery of
anticancer drugs. Among various nanocarriers, biodegrad-
able polymer based poly(lactic-co-glycolic acid) (PLGA)
nanoparticles was selected due to its excellent systemic
characteristics and biodegradability. Several studies have
reported that nanosized PLGA NP would be in the ideal
range of EPR effect as well as to avoid reticuloendothelial
system (RES) mediated clearance [18]. In the present
study, PEGylated PLGA NP was developed for the delivery
of multiple anticancer drugs.
The study was aimed at investigating the synergistic
and enhanced apoptosis effect of unique combinational
regimen. The most common treatment for osteosarcoma
is the combination of therapeutic approaches and there-
fore in this study, two drugs were combined. We
hypothesized that these two chemotherapeutic drugs
when administered simultaneously would increase the
therapeutic efficacy of cancer chemotherapy. For this
purpose, PTX and ETP were co-encapsulated in PEGy-
lated PLGA NP and evaluated its therapeutic efficacy.
The dynamic light scattering analysis and morphology
analysis were carried out to optimize the formulations.
Drug release study was performed using dialysis method.
We have evaluated the cytotoxic effect of individual and
combined drugs in MG63 and Saos-2 osteosarcoma cell
lines. The synergistic effect of combinational regimen
was characterized by cell cycle analysis and apoptosisassay. This is the first study to depict the therapeutic
efficacy of unique combination of PTX and ETP.
Results and discussion
Osteosarcoma (OS) is one of the most prevalent malig-
nant bone cancers affecting adolescents aged between 10
and 24 years. In the clinical settings, implementation of
chemotherapy greatly reduced the incidence of OS.
However, chemotherapy suffers from the relapse and in-
efficient treatment, mainly due to the inability of single
therapeutic modality to counter the tumor cells. Cancer
therapy based on single drug remains unsatisfying due
to the complex microenvironment of cancer cells along
with the drug resistance mechanisms. . In this regard,
combination therapy has been considered as a promising
strategy to improve therapeutic efficiency and to
minimize side effects. In the present study, paclitaxel
(PTX) and etoposide (ETP) were selected as a unique
drug combination for the effective treatment of OS. PTX
has been known to interfere with microtubule function,
while, ETP stabilizes the enzyme-DNA complex, result-
ing in mutagenesis, chromosomal translocation, and cell
death. Nanoparticulate system has remarkably enhanced
the therapeutic efficacy of anticancer drugs. The delivery
system could result in more favourable pharmacokinetic
profile, prolong blood circulation, and could potentially
enhance the accumulation of drug in the cancer tissues
via passive EPR effect. In this regard, PLGA nanoparticles
have been reported to possess important characteristics
such as excellent biocompatibility and biodegradability.
Therefore, in the present study, PLGA NP has been used
to incorporate two drugs. In order to prolong the systemic
blood circulation time, PLGA NP was surface modified
with PEG moiety that can endow the antifouling effect
(Figure 1A).
Physicochemical characterization of drug-loaded PLGA NP
The PLGA NP showed a high entrapment efficiency of
92.5 ± 5.6% for both the drug with a high loading cap-
acity of 13.6 ± 2.8%. The high entrapment efficiency was
attributed to the hydrophobic nature of anticancer
drugs. Dynamic light scattering (DLS) technique was
used to determine the particle size and size distribution.
DLS showed that the average particle size of NP was
around 100 ± 3.68 nm with uniform dispersion of parti-
cles (PDI, 0.14 ± 0.005) (Figure 1B). The nanosized par-
ticle along with PEG surface modification could
potentially evade the macrophage-based clearance sys-
tem and could preferentially accumulate in the cancer
tissues via passive EPR effect (extravasate from the
bloodstream) [19]. The PLGA NP showed a surface
charge of +20 mV which is in the range of excellent col-
loidal stability. The size was further confirmed by TEM
imaging (Figure 1C). The particle size from TEM (70 ±
Figure 1 Schematic illustration. (A) Schematic representation of assembly of PLGA polymers and paclitaxel and etoposide towards the
formation of drug-loaded nanoparticles. Schematic illustration of self-assembling process of polymeric nanoparticles. (B) Typical size distribution
analysis of PLGA NP by dynamic light scattering technique (C) transmission electron microscope (TEM) imaging of drug-loaded PLGA NP.
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analysis (100 ± 3.68 nm). The discrepancies in sizes were
due to that fact that TEM image was acquired on dry
samples under vacuum whereas the DLS profile was ob-
tained in an aqueous solution.
In vitro release study
PTX (Log P ~ 3.96) and ETP (Log P ~ 1.16) were encap-
sulated into PLGA NP in 1:1 molar ratio. As shown in
Figure 2, no initial burst release phenomenon wasFigure 2 Release profile of PTX and ETP from PTX-ETP/PLGA NP incub
incubated at 37°C in a rotary shaker (100 rpm). The data are presented as mobserved for both the drugs. The drugs (PTX and ETP)
released in a sustained manner from the nanoparticulate
systems up to 120 h study period. It has to be noted
that, PTX and ETP has different release pattern with lat-
ter released relatively faster than that of PTX which was
releasing slowly until the end of release study. For ex-
ample, at the end of 24 h, approximately 15 ± 3.5% of
PTX released comparing to that of 25 ± 2.6% ETP from
PLGA NP. By 120 h, 90 ± 3.64% of ETP released from
the NP, whereas only 50 ± 4.6% of PTX released duringated at phosphate buffered saline (pH 7.4). The samples were
ean ± SD (n = 3).
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in release pattern among two drugs might be due to differ-
ent hydrophobicity and position of drugs in the PLGA
core. Nevertheless, a sustained release profile for both the
drugs would be beneficial for the efficient cancer therapy.
Furthermore, a sequential release of drugs would activate
the cell apoptosis in cancer tissues.
In vitro cytotoxicity analysis
The success of nanoparticulate drug delivery system
relies on the safety and biocompatibility of delivery sys-
tem in the in vivo environment. In the present study,
biocompatibility of PEGylated PLGA nanoparticles
were studied in MG63 and Saos-2 osteosarcoma cancer
cells (Figure 3A, B). The results revealed that the nano-
particles were non-toxic and biocompatible at highest
tested concentration. In both the cell lines, cell viabil-
ities remained at more than 90% exhibiting its excellent
safety profile. Such kind of non-toxic nature of poly-
mers or nanoparticles is an ideal candidate for in vivo
applications.
Free PTX, free ETP, free PTX/ETP, and PTX-ETP/
PLGA NP was tested in these cell lines. In MG63 cells,
free drug and formulations exhibited a time-dependent
and dose-dependent cytotoxicity (Figure 4A-D). Especially,
PTX showed higher cytotoxic effect than ETP across all
the concentration on different time points. As expected,
combination of PTX/ETP substantially reduced the via-
bility of cancer cells. Importantly, PTX-ETP/PLGA NP
significantly arrested the growth of cancer cells. For ex-
ample, PTX and ETP showed a cell viability of 65% and
72%, respectively, while combinational nanoparticle ex-
hibited only 51% viability of cells indicating its superior
anticancer effect [20]. The enhanced anticancer effect
of PTX-ETP/PLGA NP was due to the controlled re-
lease of therapeutic drugs and high intracellular con-
centrations [21]. It is well known that free drug easily
diffuse into the cell membrane whereas micellar drug
takes a specific cellular internalization pathway and re-
leases the drug in a systemized manner. Similar trendFigure 3 In vitro cytotoxicity of blank polymeric nanoparticles at vari
were incubated with blank PLGA NP for 24 h and the cytotoxicity assay wawas observed in Saos-2 cancer cells however it was
relatively less sensitive to anticancer drugs comparing
to that of MG63 cells.
IC50 value was calculated to quantitate the amount of
drug required to kill 50% of cancer cells. The IC50 value
was calculated from GraphPad prism (version5) soft-
ware. The IC50 values of free PTX, free ETP, free PTX/
ETP, and PTX-ETP/PLGA NP were 4.56, 6.12, 3.82, and
1.45 μg/ml respectively in MG63 cells after 24 h incuba-
tion. In case of Saos-2 cells, IC50 values were 5.26, 7.15,
4.18, 1.98 μg/ml, respectively for all this formulations.
The IC50 value clearly showed the superior performance
of combinational nanoparticles. Moreover, it can be seen
that Saos-2 cancer cell showed higher IC50 value than
comparing to MG63 cancer cells. The combinational
nanoparticulate formulations induced greater cancer cell
killing potency than the cocktail free drugs. Moreover
our results are consistent with the report that nanoparti-
cles exhibit higher cytotoxicity owing to its higher cellular
uptake [22].
In vitro cellular uptake
The fluorescent labelled PLGA NP was incubated for
1 h, 2 h, and 3 h, respectively. As seen, NP showed a def-
inite uptake within 1 h of incubation time. Consistently,
cellular uptake increased with the increase in the incu-
bation time of NP (Figure 5A). The results clearly dem-
onstrate the time-dependent cellular internalization of
NP which will increase the intracellular concentration of
anticancer drugs leading to enhanced chemotherapeutic
effect [23].
Cellular internalization and mechanism of cellular up-
take was further investigated using confocal laser scanning
microscopy. For this purpose, MG63 cells were incubated
with Rho-B loaded PLGA NP at 37°C. As seen, nano-
particles were internalized via endocytosis process and
accumulated in the cytoplasmic region (Figure 5B). In
the merged image, presence of NP in the cytosol and
DAPI stained nuclei were clearly differentiated. It could
be expected that the NP after internalization will moveous concentrations against MG63 (A) Saos-2 cells (B). The cells
s performed by MTT reagent.
Figure 4 In vitro cytotoxicity of free PTX, free ETP, free PTX/ETP, and PTX-ETP/PLGA NP against MG63 (A, B) Saos-2 cells (C, D) incubated
for 24 and 48 h. The cytotoxicity of formulations was evaluated by MTT assay. The data are presented as mean ± SD (n = 6).
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ment where it will release its therapeutic load [24].
After cellular internalization via endocytosis pathway,
drug-loaded PLGA NP could greatly reduce the drug
efflux from cytosol and it will enhance it interactions
with the cellular components [25].Apoptosis assay
Apoptosis is a programmed, physiological mode of cell
death which plays an important role in tissue homeosta-
sis. As a programmed cell death, cell apoptosis could be
marked by a series of morphological and biochemical
changes. The flipping of phosphatidylserine (PS) and loss
in membrane potential are standard parameters for
apoptosis detection. In this study, cell apoptosis was de-
termined by Annexin V FITC and PI staining in MG63
cancer cells. The scatter plot has four quadrants: lower
left quadrant (Q3) indicates viable cells (Annexin − ve,
PI − ve), lower right quadrant (Q4) indicates early apop-
totic cells (Annexin + ve, PI − ve), upper right quadrant(Q2) indicates late apoptotic cells (Annexin + ve, PI + ve)
and upper left quadrant (Q1) indicates necrotic cells (PI +
ve). In our experiment, we have treated MG63 cells with
individual drugs as well as combinational drugs (with and
without carrier). As seen (Figure 6), PTX induced apop-
tosis with much of cells in early apoptosis chamber and
fewer cells in late apoptosis chamber. On the other hand,
ETP has least effect on the cellular apoptosis with only
few cells in apoptosis chamber. However when PTX and
ETP were combined, it induced a significantly higher
apoptosis than did the individual drugs. Approximately
15% of cells were in late apoptosis stage and 10% of cells
in early apoptosis stage. As expected, PLGA NP remark-
ably induced a greater apoptosis of MG63 cells with more
than 20% of cells in late apoptosis chamber (p < 0.01). The
results clearly showed that combinational drugs improved
the therapeutic index of each drug and resulted in super-
ior anticancer effect [26]. Although, synergistic effect was
seen in combined cocktail drugs, advantage of loading in
nanoparticulate system would be to release the drug in an
optimized sequential pattern [27].
Figure 5 Cellular uptake analysis. (A) Flow cytometry analysis of in vitro cellular uptake of PLGA NP in a time dependent manner. The PLGA
nanoparticle was loaded with Rhodamine B as a fluorescent dye. (B) Confocal microscopy images of MG63 cells. Cells were treated with
PTX-ETP/PLGA NP and incubated for 1 h. Nuclei were stained with DAPI and Rho B fluorescence was observed in the cytoplasm.
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Cell cycle progression is regarded as a hallmark of can-
cer progression and therefore effective strategy to inhibit
cancer cell progression remains the primary strategy. In
the present study, cell cycle progression has been ana-
lysed after treating with free PTX, free ETP, free PTX/
ETP, and PTX-ETP/PLGA NP for 20 h (Figure 7). Re-
sults clearly showed that PTX arrests the cancer cell at
G2/M phase of cell cycle, while ETP has relatively lesser
effect on the cell cycle arrest. The combination of PTX/ETP however showed a significant (p < 0.01) cell cycle
arrest G2/M phase when compared to native free drugs
(individual). It has to be noted that nanoparticle encap-
sulation (PTX-ETP/PLGA NP) drugs arrested maximum
number of cells in the same concentration as that of single
drugs. The synergistic activity of combined drugs effect-
ively checked the growth of cancer cells. Earlier, Park et al.
reported that NP is more effective in controlling cell cycle
progression than native free drugs [22]. Although the
synergistic effect was observed with cocktail drugs
Figure 6 Flow cytometer analysis of cell apoptosis using annexinV-FITC and PI staining. The MG63 cells were exposed with free PTX, free
ETP, free PTX/ETP, and PTX-ETP/PLGA NP at a concentration of 1000 ng/ml and incubated for 20 h. **p < 0.01 is the statistical difference between
the combinational nanoparticles and individual free drugs.
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lease the drug in a ratiometric manner to the tumor
tissue, in vivo. The greater inhibitory effect of nanopar-
ticle combination would be of great advantage during
systemic cancer therapy [28].Conclusion
In conclusion, PTX and ETP co-loaded PLGA NP was
successfully developed and characterized for its synergis-
tic activity against osteosarcoma cancer cells. Various
physicochemical and biological parameters were assessed
Figure 7 Effect of free drug and drug loaded NPs on the cell cycle distribution of MG63 cells. For cell cycle analysis, cells were treated
with respective formulation and 24 h post treatment, stained with PI and RNAse before flow cytometer analysis. The region marked M1, M2, M3
and M4 represent G1, S, G2/M and G0 phase respectively, of the cell cycle. **p < 0.01 is the statistical difference between the combinational
nanoparticles and individual free drugs.
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exhibited a controlled sequential release pattern for both
the drugs. The PLGA NP loaded drugs showed a potent
anticancer effect in MG63 and Saos-2 cancer cells in a
time and concentration dependent manner. Additionally,NPs showed an appreciable uptake in MG63 cells in a
time-based manner. Co-delivery of anticancer drugs
resulted in enhanced cell cycle arrest and apoptosis. The
results clearly showed that combinational drugs remark-
ably improved the therapeutic index of chemotherapeutic
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bination would be of great advantage during systemic can-
cer therapy. Taken together, multiple drug-loaded PLGA
NP would be a promising cancer drug delivery system for
the treatment of osteosarcoma.
Materials and methods
Methods
PLGA (50:50, MW 15000) was procured from the
Shandong Institute of Medical Instruments (Shandong,
China). PEG-PLGA was procured from Sigma-Aldrich,
China. Paclitaxel was purchased from Xian Aladdin
Biological Technology Co., Ltd, China. Etoposide was
procured from Sigma-Aldrich, China. All other chemicals
were reagent grade and used without further purifications.
Preparation of drug-loaded PEGylated PLGA nanoparticles
PEGylated PLGA NP was prepared by solvent evapor-
ation method. In brief, PTX and ETP (10% w/w of poly-
mer) was dissolved in 1 ml of ethylacetate and 200 mg
of PLGA and 20 mg of PEG-PLGA was separately dis-
solved in 1 ml of ethylacetate solution. Both the organic
solutions were dissolved in 5% Pluronic 188 (pH 9.2) so-
lution and sonicated for 2 min. 5 ml of 2% Pluronic 188
solution was added to the pre-formed primary w/o
emulsions and sonicated for additional 2 min to form a
w/o/w emulsions. The resulting double emulsion was in
turn poured into 50 ml of 2% Pluronic 188 solution and
mechanically stirred for 1 h at 1000 rpm. The drug
loaded nanoparticles were washed, centrifuged, resus-
pended and stored at 4°C until further use.
Particle size and zeta potential analysis
The particle size, size distribution, and zeta potential
analysis were carried out by light scattering technique.
Zeta Sizer 3000 HS (Malvern Instruments, UK) was used
to measure the particle size at a fixed angle of 90° at 25°C.
The formulations were suitably diluted with distilled water
such that the mean count rate remains around 200. All
measurements were performed in triplicate and presented
as mean ± SD.
Nanoparticles morphology
Transmission electron microscope (JEOL JEM-200CX)
was used to characterize the morphology of nanoparticles.
Briefly, liquid sample was placed in a carbon coated cop-
per grid and counter stained with phosphotungistic acid,
followed by air drying for 2 h. The samples were examined
under acceleration voltage of 100 kV in conventional
TEM mode.
Drug loading
The drug loading capacity (DLC) and drug loading effi-
ciency (DLE) was calculated using HPLC method. Thedrug formulations were filtered using Amicon centrifu-
gal tube (MW cut off-3000). The filtrate was collected to
determine the amount of the free drug (unentrapped) re-
mains of the total amount of drug added. Few microliter
of filtrate was injected into the HPLC column. Earlier,
separate calibration curve has been built for PTX and
ETP. The calibration equations were used to determine
the amount of drug in the filtrate:




DLE ¼ Weight of drug loaded=
total weight of drug added
 !
 100%
In vitro drug release
The release study was performed by dialysis method.
Briefly, PTX/ETP-loaded PLGA nanoparticles were
freeze dried. The release study was performed in physio-
logical media (pH 7.4; phosphate buffered saline) at 37°C.
The freeze dried samples were dispersed in 1 ml of water
and sealed in dialysis membrane tubing (MW cut off:
3000). The sealed membrane was placed in a 10 mL of re-
lease media and the whole assembly was in turn placed in
shaking water bath maintained at 37°C. At selected time
intervals, 1 ml of release media was withdrawn and re-
placed with equal volume of fresh medium. The amount
of each drug released in the media was determined using
HPLC method. Agilent 1100 equipped with a G1311A
pump, a G1314A programmable diode array detector
(DAD) and a G1313A auto-injector was used. C18
(250 mm× 4.6 mm ID, 5 μm) analytical column was used.
Different mobile phase was used to characterize the
concentration of individual drug released.
Cell culture
MG63 and Saos-2 osteosarcoma cells were cultured in
the DMEM growth medium supplemented with 10%
foetal bovine serum, 1% -L-glutamine, and 1% penicillin/
streptomycin mixture. The cells were grown in ambient
conditions of 5% CO2 at 37°C. The cells were passaged
when it reached 90% confluency.
Cytotoxicity assay
The cytotoxicity assay was measured by 3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay. It is based on the reduction of yellow
MTT by mitochondrial succinate dehydrogenase. MTT
enters the live cells and reduced into insoluble formazan
complex. For this, MG63 and Saos-2 osteosarcoma cells
were seeded at a density of 1 × 104 in a 96-well plate.
After 24 h, cells were exposed to blank polymer, free
PTX, free ETP, PTX/ETP and PTX-ETP/PLGA NP at
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and 48 h accordingly. At each time point, plate was re-
moved and treated with 100 μl of MTT solution (5 mg/ml)
to each 96-well plate and incubated for 4 h. The formed
formazan crystals were extracted by adding DMSO and
incubated for additional 30 min. The absorbance of
each plate was read at 570 nm using a microplate
reader (Thermo-Fisher, USA). All experiments were re-
peated 6 times.Cellular uptake by flow cytometry
BD FACS Calibur flow cytometer was used to determine
the uptake potential of Rhodamine B Isothiocyanate
(Rho-B) loaded PLGA NP in MG63 cancer cells. For
this, 3 × 105 cells were seeded on each well of 6-well
plate and incubated overnight. The media was replaced
with fresh media and treated with 50 μg/ml of PLGA NP
(10 μg/ml equivalent of Rho-B) and cellular uptake was
observed in a time-dependent manner (up to 3 h). Follow-
ing incubation at 37°C, cells were washed twice with PBS,
harvested, centrifuged, and resuspended in a growth
medium. The process of washing and centrifugation was
continued for 2 cycles. The cell suspension in 1 ml of PBS
was used to determine the cellular internalization.Confocal laser scanning microscopy
Cellular uptake mechanism was investigated by means
of confocal laser scanning microscopy. 3 × 105 cells were
seeded in a 6-well plate containing a cover slip. The cells
were allowed to attach for 24 h. Following day, old
media was replaced with new media and incubated with
Rho-B-loaded PLGA NP for 2 h. The cells were washed
twice with PBS and fixed with 4% paraformaldehyde for
20 min. The cells were washed again and the nuclei were
stained with DAPI solution for 10 min. The cellular in-
ternalization process was evaluated using confocal
microscopy.Cell cycle assays
The MG63 cells were seeded in a 12-well plate and the
cells were allowed to attach for 24 h. Following day, old
media was replaced with new media and exposed with
free PTX, free ETP, free PTX/ETP, and PTX-ETP/PLGA
NP for a period of 20 h. The cells were washed twice
with PBS and harvested in the presence of trypsin. Cells
were washed, centrifuged, and resuspended. Cells were
suspended in 100 μl of PBS and 100 μl of reagent 1
(RNase (0.2 mg/mL) and Triton X-100) was added. After
5 min of vigorous stirring, 1 ml of reagent 2 (propidium
iodide) was added, vortexed and incubated in dark for
60 min. The stained samples were then analysed using
BD FACS Calibur flow cytometer.Determination of apoptosis assays
The apoptosis assay was carried out by annexin V/PI
double stain assay. The MG63 cells were seeded in a 12-
well plate and allowed to attach for 24 h to the walls.
Following day, old media was replaced with new media
and exposed with free PTX, free ETP, free PTX/ETP, and
PTX-ETP/PLGA NP at a concentration of 1000 ng/ml
and incubated for 20 h. The cells were washed twice with
PBS and harvested in the presence of trypsin. The cells
were centrifuged, and resuspended again in PBS. After
final washing procedure, cells were redispersed in binding
buffer and stained with FITC-annexin V and PI for
20 min. The cells were immediately analysed using BD
FACS Calibur flow cytometer.
Statistical analysis
Statistical analysis was performed by Student’s t-test for
two groups, and one-way ANOVA for multiple groups.
The significance level was set at a probability of P < 0.05.
All results were reported as the mean ± standard deviation
(SD).
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